Nordic Nanovector
Dr Nieba joined Nordic Nanovector on 1 December 2019 from Bayer AG where he served in various operational and strategic roles, Dr Nieba was most recently responsible for driving Bayer's Chemistry, Manufacturing and Controls (CMC) strategy for biologicals. He joined Bayer in 2016 following 13 years at F. Hoffmann-La Roche Ltd., where he held various leadership roles in clinical, operations, supply planning, biologics technology and technical business development. Prior Dr Nieba worked for Cytos Biotechnology where he served as Head of Therapeutic Vaccine Research.
This person is not in any offices
Nordic Nanovector
Nordic Nanovector is committed to developing and delivering innovative therapies to patients to address major unmet medical needs. The Company aspires to become a leader in the development of CD37-targeted therapies for hematological cancers and immune diseases.